A treatment with erythropoietin as short as eight weeks led to significant changes in gene expression in calf muscle biopsies from FRDA patients, which (1) are consistent with the properties of this hormone and (2) are clearly detectable despite skeletal muscle not being its primary target [15]. The gene discussed is EPO; the disease is Friedreich ataxia.